Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...
D2’ solution that bridges the gap between humans and machines, says the company’s founder and CEO Peter Harding.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback